Skip to main content
. 2015 Dec 1;5:17288. doi: 10.1038/srep17288

Figure 5. Relative binding affinity of various peptide motifs to the FXR LBD in the presence of avermectin analogues as determined by peptide competition assays.

Figure 5

Various unlabeled peptides (20 μM) are used to compete off the binding of the biotin-labeled SRC2-3 LXXLL motif to FXR LBD in response to 1 μM ivermectin, abamectin, doramectin, or 0.5 μM GW4064, respectively. Values are the means ± SEM of three independent experiments. Sequences of peptides used in the AlphaScreen assays are as described previously28.